Neomics is Biotechnology in South Korea that focus on synthetase antibody business. Founded in 2005. They cover business area such as developer, diagnostic, therapeutic, human incurable disease, cancer, anti-aminoacyl-trna synthetase antibody polyclonal and monoclonal product, doctor, custom antibody production, protein expression, purification service.
2005
( 19 years old in 2024 )
Synthetase Antibody
-
Gwanggyuro 145 (Iui-dong, Advanced Institute of Convergence Technology 9 fl. B-dong)
Yeongtong-gu
Suwon-si, Gyeonggi-do 443-270
South Korea
Private
developerdiagnostictherapeutichuman incurable diseasecanceranti-aminoacyl-trna synthetase antibody polyclonal and monoclonal productdoctorcustom antibody productionprotein expressionpurification service
* We use standard office opening hours in near Neomics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Neomics is Biotechnology business from South Korea that founded in 2005 (19 years old in 2024), Neomics business is focusing on Synthetase Antibody.
Neomics headquarter office and corporate office address is located in Gwanggyuro 145 (Iui-dong, Advanced Institute of Convergence Technology 9 fl. B-dong) Yeongtong-gu Suwon-si, Gyeonggi-do 443-270 South Korea.
Neomics was founded in South Korea.
In 2024, Neomics is currently focus on synthetase antibody sector.
Above is snippet of Google Trends for "synthetase antibody" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Neomics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
